Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options

Next Previous
Search
Trial Profile

Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olorofim (Primary)
  • Indications Aspergillosis; Mycoses
  • Focus Therapeutic Use
  • Acronyms FORMULA-OLS
  • Sponsors F2G

    • Most Recent Events

    • 14 Mar 2024 This trial has been completed Poland, according to European Clinical Trials Database record.
    • 13 Mar 2024 This trial has been completed in Belgium and Germany (End date:10 Feb 2023) according to European Clinical Trials Database record.
    • 21 Oct 2023 According to a F2G media release, data from this study will be presented at 11th Congress on Trends in Medical Mycology (TIMM) 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top